Previously, I was scrambling to go public in the United States，Recently, it has led the delegation to the market for privatization。The listing path of China Pharmaceutical Company is changing。

    Xianmin Pharmaceuticals officially announced the plan that it intends to privatize。Before that，Already have Tongji Hall、Kanghui Medical and other 12 pharmaceutical companies have completed the privatization delisting or forced to transfer to the market outside the market。

    Analysis refers to，The privatization intention of the Chinese stock group of the pharmaceutical sector is returning to A shares or H shares，but，Stake Sports Bettingstake betting appIt is not easy to re -IPO after delisting。Data display，As of now, there are still 60 pharmaceutical -related companies in the queue of A shares。

    Elberry first

    The news of the privatization of Xianyin Pharmaceutical does not exceed market expectations。According to the privatization plan recently announced by Xianyin Pharmaceutical，The acquisition group led by the company's chairman Ren Jinsheng will acquire all the pioneers that are not yet held in general shares，Prices of $ 9.56 per A D S (US deposit shares) are pure cash，Agreement of $ 4.78 per ordinary share。The total estimation of this bid for the pioneer pharmaceutical industry is about 500 million US dollars。

    This is no longer the first privatization plan for Chinese concept pharmaceutical stocks，Previously, Guizhou Tongji Hall, a subsidiary of Fosun, has successfully privatized。But the pioneer pharmaceutical industry is the first chemical pharmaceutical company in China to achieve listing on the NYSE，Its privatization solution is still widely interpreted by the industry。

    & ldquo;，In fact, starting from the moment of setting on the New York Stock Exchange，It is destined to be privatized。& rdquo; Wang Jinru, president of Manhattan Capital Management Co., Ltd.。In his opinion，Pharmaceutical companies such as the concepts of Chinese concepts originally chose to go public in the United States，In fact, it is forced by the environment。At that time，China does stake sports betting appMy stake betting appnot have the GEM yet is the main reason。

    According to external speculation，Pioneer Pharmaceuticals after delisting from the NYSE，I will definitely return to A shares or H shares。but，The aspect of the pioneer pharmaceutical industry will not comment，Wang Yanan, the person in charge of media affairs, has been in a state of no one to answer。

    The disadvantage of overseas listing is getting up

    The fastest change in the market attitude towards the US market is Norcon creatures.

    This largest domestic blood condenase supplier landed in Nasdaq in December 2009，I proposed a preliminary offer for non -binding，and reached a privatization delisting agreement at the fastest speed at the fastest speed。To the market person，Whether it is Norcon Bio，Still after 6 years at the New York Stock Exchange, the first time I finally decided to delist，In the end, it is a pragmatic choice。

    & ldquo;，Many people don’t understand Chinese pharmaceutical companies，Local analysts have rarely tracking Chinese conceptual pharmaceutical stocks。In addition to Yaoming Kangde、Mai Rui，Other companies listed in the United States are generally low P / E ratio，The transaction value is also very low，Compared to A shares or H shares，Disadvantages are getting more and more obvious。& rdquo; A pharmaceutical industry who is familiar with the US stock market says，In his opinion，Trading expenses of high -company US stocks，It is also one of the factors that make Chinese concept stocks choose privatization。

    It is also difficult to return to the Mainland

    stake betting appMy stake betting appWith the retreat of the Chinese concept pharmaceutical stocks，Bio -life、Kaisai Bio、Anqing Pharmaceutical's original company originally wanted to log in to the US capital market，Also hit the backdoor drum，One after another withdrawing the IPO application in the United States。

    but，For those pharmaceutical companies that are interested in returning to China or the Hong Kong market,，Perhaps it is not a good timing。Data show from the CSRC issued a review committee，As of now，A total of more than 900 companies nationwide are queuing up。and more than 900 queuing companies，The proportion of pharmaceutical companies reaches 6.57%，That is to say, there are currently about 60 pharmaceutical related enterprises in line in line。

    In addition，Affected by the development of the macroeconomic face and the development of the pharmaceutical industry，Chinese conceptual pharmaceutical company, including pilot pharmaceutical industry, no longer has the proud performance of the past。Take the pilot pharmaceutical as an example，When it was listed in 2007,，Xianyin Pharmaceutical realized a net profit of 3.01 billion yuan。Subsequent 2008，The net profit of Xianyin Pharmaceutical exceeded 3.5 billion yuan。At present，The net profit of Xianmin Pharmaceutical has shrunk sharply。Annual report display，Xianmin Pharmaceutical's 2012 net profit was only 5.7 billion yuan，Falling a sharp drop of Stake Sports Betting68.07%year -on -year，Among stake betting appthe fourth quarter of the losses of about 20.8 million yuan。